GSK plc (GSK) Stock: Price, Forecast & Analyst Target
GSK plc (GSK) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $48.58 (-1.34%), as of the Nov 18, 2026 trading session; market cap $97.4B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
GSK plc · GSK · NYSE · Healthcare · Drug Manufacturers - General
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · GSK (GSK)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.
- EPS beat 8 of the last 8 reports
- Altman Z 1.80 · Piotroski F 8
- ROE 28.3% · ROA 9.6% · current ratio 0.86
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 83 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 77 | Strong | |
| 77 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $48.58 | |
| Change on the day | -1.34% | |
| 52-week range | $45.81–$61.70 | |
| Market capitalisation | $97.4B | — |
| Price / earnings (trailing) | 17.31 | |
| Shares traded on the day | 2.02M | |
| Beta (volatility vs the S&P 500) | 0.28 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for GSK (GSK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is GSK (GSK), and what does it report?
Short answer
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. GSK plc (GSK) is listed on NYSE. Healthcare / Drug Manufacturers General SEC filing business address: 79 NEW Oxford Street, London, WC1A 1DG. It employs 66,841 people and is led by Luke Victor Miels. The market values it at $97.4B.
What do the latest results show for GSK (GSK)?
Short answer · as of
Against analyst estimates the company has EPS beat 8 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $11.82B Oct 28, 2026
- Latest report · revenue estimate
- $11.78B Oct 28, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 28, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 28, 2026 | $11.82B | $11.78B | $1.4700 | $1.4000 |
| Jul 28, 2026 | $11.18B | $11.02B | $1.3600 | $1.2700 |
| Apr 29, 2026 | $10.30B | $10.23B | $1.2400 | $1.1600 |
| Feb 4, 2026 | $11.78B | $11.41B | $0.6800 | $0.6400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | £8.55B | £2.01B | £0.98 (diluted) |
| Q4 FY2025 | £8.62B | £636M | £0.31 (diluted) |
| Q1 FY2026 | £7.63B | £1.74B | £0.85 (diluted) |
| Q2 FY2026 | £8.41B | £435M | £0.21 (diluted) |
What are the financial strengths and risks for GSK (GSK)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, positive momentum as strengths. The distress and quality screens read Altman Z 1.80 · Piotroski F 8. Trailing ratios: ROE 28.3% · ROA 9.6% · current ratio 0.86.
What should you watch next at GSK (GSK)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027. Current published price targets run low $55.90 · high $60.00 · consensus $57.95 · median $57.95 against a quoted price of $48.58 (as of Nov 18, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No forward revenue or earnings estimate is on file.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does GSK compare with its peers?
Short answer
GSK's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $1084.43 Nov 18, 2026 | $125B | 92 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| $178.76 Nov 18, 2026 | $277B | 85 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $286.01 Nov 18, 2026 | $506B | 83 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $81.34 Nov 18, 2026 | $104B | 81 5-pillar Nov 18, 2026 | |
| GSK (GSK) — this page | $48.58 | $97.4B | 77 |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $55.90 – $60.00
- Consensus target
- $57.95
- Median target
- $57.95
Consensus record · Captured .
Measured against a quoted price of $48.58 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GSK in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.11% | $26.43M | Added +8.8% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about GSK (GSK)?
GSK Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do GSK vaccines change the way its business should be read?
GSK earns from prevention as well as treatment, with vaccines addressing shingles, meningitis, respiratory syncytial virus, influenza and polio. Immunization uptake therefore matters alongside demand for HIV, oncology, respiratory, immunology and anti-infective medicines.
Why are CureVac, Wave Life Sciences and Elsie Biotechnologies relevant to GSK?
CureVac supports messenger RNA influenza work, while Wave Life Sciences and Elsie Biotechnologies contribute oligonucleotide platforms. These collaborations extend GSK’s research reach beyond programs developed solely inside the company.
What is the GSK stock price today?
The last price recorded for GSK plc (GSK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GSK price target?
The analyst consensus price target for GSK plc (GSK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 32 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com